Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Against Maravai LifeSciences Holdings, Inc.
New York, NY – April 6, 2025 – Bronstein, Gewirtz & Grossman, LLC, a leading national securities fraud law firm, reminds investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI) and certain of its officers. The lawsuit, which was filed in the United States District Court for the Southern District of New York, alleges that the Company and its officers violated the federal securities laws.
Class Definition
The lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired Maravai securities during the period from August 7, 2024, to February 24, 2025, both dates inclusive (the “Class Period”).
Allegations
According to the complaint, Maravai and its officers made false and misleading statements regarding the Company’s financial condition and business prospects. Specifically, the complaint alleges that the defendants failed to disclose that Maravai was experiencing operational challenges, including delays in the commercialization of certain products and a decline in sales.
Impact on Individual Investors
If you purchased Maravai securities during the Class Period, you may be eligible to receive compensation for your losses. You can join the class action by contacting the law firm before the deadlines set forth in the notice. The notice provides detailed information about the lawsuit and the claims process.
Impact on the World
The impact of this lawsuit on the world at large may depend on the outcome of the case. If the defendants are found liable, it could send a message to other publicly traded companies to be more transparent about their financial condition and business prospects. It could also result in increased scrutiny of the biotech industry, which has seen a number of high-profile securities fraud cases in recent years.
Conclusion
Bronstein, Gewirtz & Grossman, LLC encourages investors who purchased Maravai securities during the Class Period to contact the firm for more information about the class action and their potential legal rights. The firm represents investors from around the world and takes pride in providing advocacy and expertise in securities and investment fraud cases.
Investors who are not interested in joining the class action but have information that may be helpful to the investigation are encouraged to contact the firm as well. The firm offers a contingency fee arrangement, meaning that it only gets paid if the case is successful.
Contact Information
Bronstein, Gewirtz & Grossman, LLC
- 200 Park Avenue
- Suite 1612
- New York, NY 10166
- Phone: 212-697-1001
- Fax: 212-697-1007
- Email: [email protected]
